Search Results - "Pankov, Dmitry"

Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy by Dalton, Tanner, Doubrovina, Ekaterina, Pankov, Dmitry, Reynolds, Raymond, Scholze, Hanna, Selvakumar, Annamalai, Vizconde, Teresa, Savalia, Bhumesh, Dyomin, Vadim, Weigel, Christoph, Oakes, Christopher C., Alonso, Alicia, Elemento, Olivier, Pan, Heng, Phillip, Jude M., O'Reilly, Richard J., Gewurz, Benjamin E., Cesarman, Ethel, Giulino-Roth, Lisa

“…Despite advances in T-cell immunotherapy against Epstein-Barr virus (EBV)-infected lymphomas that express the full EBV latency III program, a critical barrier…”
Get full text

PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates by Veach, Darren R, Storey, Claire M, Lückerath, Katharina, Braun, Katharina, von Bodman, Christian, Lamminmäki, Urpo, Kalidindi, Teja, Strand, Sven-Erik, Strand, Joanna, Altai, Mohamed, Damoiseaux, Robert, Zanzonico, Pat, Benabdallah, Nadia, Pankov, Dmitry, Scher, Howard I, Scardino, Peter, Larson, Steven M, Lilja, Hans, McDevitt, Michael R, Thorek, Daniel L J, Ulmert, David

“…Most patients with prostate cancer treated with androgen receptor (AR) signaling inhibitors develop therapeutic resistance due to restoration of AR…”
Get full text

Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2 by Hoseini, Sayed Shahabuddin, Dobrenkov, Konstantin, Pankov, Dmitry, Xu, Xiaoliang L., Cheung, Nai-Kong V.

“…Chimeric antigen receptors (CAR) and bispecific antibodies (BsAb) are two powerful immunotherapy approaches for retargeting lymphocytes toward cancer cells…”
Get full text

PERFORMANCE AUDIT FOR STATE PROGRAMMES IN THE REPUBLIC OF KAZAKHSTAN by Alikulova, Laura, Saule Spatayeva, Pankov, Dmitry, Sembiyeva, Lyazzat

“…This study is necessitated by a detailed analysis of the types of audit, in particular, the performance audit of the quasi-public sector. The purpose of this…”
Get full text

TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies by Ahmed, Mahiuddin, Lopez-Albaitero, Andres, Pankov, Dmitry, Santich, Brian H, Liu, Hong, Yan, Su, Xiang, Jingyi, Wang, Pei, Hasan, Aisha N, Selvakumar, Annamalai, O'Reilly, Richard J, Liu, Cheng, Cheung, Nai-Kong V

“…EBV infection is associated with a number of malignancies of clinical unmet need, including Hodgkin lymphoma, nasopharyngeal carcinoma, gastric cancer, and…”
Get full text

96 Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo by Pankov, Dmitry, Eleftheriadou, Ioanna, Domogala, Anna, Brett, Sara, Patasic, Lea, Kijewska, Magdalena, Thripp, Gary, Euesden, Jack, Klapwijk, Jan, Soor, Katrina, Damm, Miriam, Hill, Mark D, Georgouli, Mirella, Shalabi, Aiman, Britten, Cedrik

“…BackgroundNY-ESO-1–specific T cells (letetresgene autoleucel [lete-cel] GSK3377794) are autologous CD4+ and CD8+ T cells transduced to express a high-affinity…”
Get full text

Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1 by Dao, Tao, Pankov, Dmitry, Scott, Andrew, Korontsvit, Tatyana, Zakhaleva, Victoriya, Xu, Yiyang, Xiang, Jingyi, Yan, Su, de Morais Guerreiro, Manuel Direito, Veomett, Nicholas, Dubrovsky, Leonid, Curcio, Michael, Doubrovina, Ekaterina, Ponomarev, Vladimir, Liu, Cheng, O'Reilly, Richard J, Scheinberg, David A

“…A bi-specific antibody that binds both T cells and a tumor-specific intracellular antigen shows therapeutic promise in mouse models of cancer. Intracellular…”
Get full text

Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1+ leukemias by Doubrovina, Ekaterina, Carpenter, Taissia, Pankov, Dmitry, Selvakumar, Annamalai, Hasan, Aisha, O'Reilly, Richard J.

“…The Wilms tumor protein (WT-1) is widely recognized as a tumor antigen that is expressed differentially by several malignancies. However, WT-1 peptides known…”
Get full text

Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable by Codilupi, Tamara, Szybinski, Jakub, Arunasalam, Stefanie, Jungius, Sarah, Dunbar, Andrew C, Stivala, Simona, Brkic, Sime, Albrecht, Camille, Vokalova, Lenka, Yang, Julie L, Buczak, Katarzyna, Ghosh, Nilabh, Passweg, Jakob R, Rovo, Alicia, Angelillo-Scherrer, Anne, Pankov, Dmitry, Dirnhofer, Stefan, Levine, Ross L, Koche, Richard, Meyer, Sara C

“…Myeloproliferative neoplasms (MPN) dysregulate JAK2 signaling. Because clinical JAK2 inhibitors have limited disease-modifying effects, type II JAK2 inhibitors…”
Get full text

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody by Dao, Tao, Yan, Su, Veomett, Nicholas, Pankov, Dmitry, Zhou, Liang, Korontsvit, Tatyana, Scott, Andrew, Whitten, Joseph, Maslak, Peter, Casey, Emily, Tan, Taochao, Liu, Hong, Zakhaleva, Victoria, Curcio, Michael, Doubrovina, Ekaterina, O'Reilly, Richard J, Liu, Cheng, Scheinberg, David A

“…The Wilms tumor 1 (WT1) oncoprotein is an intracellular, oncogenic transcription factor that is overexpressed in a wide range of leukemias and solid cancers…”
Get more information

A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias by Dubrovsky, Leonid, Pankov, Dmitry, Brea, Elliott Joseph, Dao, Tao, Scott, Andrew, Yan, Su, O'Reilly, Richard J, Liu, Cheng, Scheinberg, David A.

“…Acute and chronic leukemias, including CD34+ CML cells, demonstrate increased expression of the Wilms tumor gene 1 product (WT1), making WT1 an attractive…”
Get full text

PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates by Veach, Darren R., Storey, Claire M., Lückerath, Katharina, Braun, Katharina, von Bodman, Christian, Lamminmäki, Urpo, Kalidindi, Teja, Strand, Sven-Erik, Strand, Joanna, Altai, Mohamed, Damoiseaux, Robert, Zanzonico, Pat, Benabdallah, Nadia, Pankov, Dmitry, Scher, Howard I., Scardino, Peter, Larson, Steven M., Lilja, Hans, McDevitt, Michael R., Thorek, Daniel L. J., Ulmert, David

Get full text

Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein by VEOMETT, Nicholas, TAO DAO, CASEY, Emily, CURCIO, Michael, KHARAS, Michael G, O'REILLY, Richard J, CHENG LIU, SCHEINBERG, David A, HONG LIU, JINGYI XIANG, PANKOV, Dmitry, DUBROVSKY, Leonid, WHITTEN, Joseph A, PARK, Sun-Mi, KORONTSVIT, Tatyana, ZAKHALEVA, Victoria

“…RMFPNAPYL (RMF), a Wilms' tumor gene 1 (WT1)-derived CD8 T-cell epitope presented by HLA-A*02:01, is a validated target for T-cell-based immunotherapy. We…”
Get full text

Therapeutic activity of a bi-specific T cell engaging, TCR-mimic monoclonal antibody to WT1 against human leukemias and cancers in mouse models by Pankov, Dmitry, Dao, Tao, Dubrovsky, Leonid

Get full text

T cell receptor mimic antibodies for cancer therapy by Dubrovsky, Leonid, Dao, Tao, Gejman, Ron S, Brea, Elliott J, Chang, Aaron Y, Oh, Claire Y, Casey, Emily, Pankov, Dmitry, Scheinberg, David A

“…The major hurdle to the creation of cancer-specific monoclonal antibodies (mAb) exhibiting limited cross-reactivity with healthy human cells is the paucity of…”
Get full text

In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME) by Pankov, Dmitry, Sjöström, Ludvig, Kalidindi, Teja, Lee, Sang-Gyu, Sjöström, Kjell, Gardner, Rui, McDevitt, Michael R, O'Reilly, Richard, Thorek, Daniel L J, Larson, Steven M, Veach, Darren, Ulmert, David

“…Preferentially Expressed Antigen in Melanoma (PRAME) is a cancer/testis antigen that is overexpressed in a broad range of malignancies, while absent in most…”
Get full text

A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity by Shono, Yusuke, Tuckett, Andrea Z, Ouk, Samedy, Liou, Hsiou-Chi, Altan-Bonnet, Grégoire, Tsai, Jennifer J, Oyler, Jennifer E, Smith, Odette M, West, Mallory L, Singer, Natalie V, Doubrovina, Ekaterina, Pankov, Dmitry, Undhad, Chandresh V, Murphy, George F, Lezcano, Cecilia, Liu, Chen, O'Reilly, Richard J, van den Brink, Marcel R M, Zakrzewski, Johannes L

“…Preventing unfavorable GVHD without inducing broad suppression of the immune system presents a major challenge of allogeneic hematopoietic stem cell…”
Get more information

Abstract 5515: WT1 specific T cells can efficiently eliminate tumorigenic ovarian carcinoma cells and prevent or inhibit the tumor growth in NOD/SCID model of ovarian carcinoma by Pankov, Dmitry, O'Reilly, Richard, Doubrovin, Mikhail, Hasan, Aisha, Doubrovina, Ekaterina

“…Abstract The Wilms tumor protein, WT-1 is expressed in over 60% of serous adenocarcinomas of the ovary. Its expression has been hypothesized to be critical for…”
Get full text

Therapeutic Efficacy and Cure Of Sensitive and T315I Pan-Resistant Human Ph+ Leukemia In Mice Using a TCR-Like Antibody To WT1/HLA-A0201 Alone, Or In Combination With Tyrosine Kinase Inhibitors by Dubrovsky, Leonid, Brea, Elliott, Pankov, Dmitry, Veomett, Nicholas, Dao, Tao, Yan, Su, Liu, Cheng, Scheinberg, David A.

“…Acute and chronic leukemias, including CD34+ CML stem cells, overexpress the Wilms tumor gene 1 (WT1) protein, making WT1 an attractive therapeutic target…”
Get full text

Native and Fc Enhanced Therapeutic Human Monoclonal Antibodies Targeting the Intracellular WT1 Oncogene Product in Leukemia by Veomett, Nicholas, Dao, Tao, Pankov, Dmitry, Yan, Su, O'Reilly, Richard J., Liu, Cheng, Scheinberg, David A.

“…Abstract 2599 The Wilms’ tumor oncogene protein (WT1) is an intracellular, oncogenic transcription factor that is over-expressed in leukemias and a wide range…”
Get full text